[go: up one dir, main page]

ES3024479T3 - Managing nephrogenic diabetes insipidus - Google Patents

Managing nephrogenic diabetes insipidus Download PDF

Info

Publication number
ES3024479T3
ES3024479T3 ES18748236T ES18748236T ES3024479T3 ES 3024479 T3 ES3024479 T3 ES 3024479T3 ES 18748236 T ES18748236 T ES 18748236T ES 18748236 T ES18748236 T ES 18748236T ES 3024479 T3 ES3024479 T3 ES 3024479T3
Authority
ES
Spain
Prior art keywords
compound
individual
pharmaceutically acceptable
stereoisomers
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18748236T
Other languages
English (en)
Spanish (es)
Inventor
Jeff Sands
Janet Klein
Ish Khanna
Sivaram Pillarisetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nephrodi Therapeutics Inc
Original Assignee
Nephrodi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nephrodi Therapeutics Inc filed Critical Nephrodi Therapeutics Inc
Application granted granted Critical
Publication of ES3024479T3 publication Critical patent/ES3024479T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES18748236T 2017-01-31 2018-01-31 Managing nephrogenic diabetes insipidus Active ES3024479T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762452616P 2017-01-31 2017-01-31
PCT/US2018/016184 WO2018144570A1 (fr) 2017-01-31 2018-01-31 Gestion du diabète insipide néphrogène

Publications (1)

Publication Number Publication Date
ES3024479T3 true ES3024479T3 (en) 2025-06-04

Family

ID=63040033

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18748236T Active ES3024479T3 (en) 2017-01-31 2018-01-31 Managing nephrogenic diabetes insipidus

Country Status (14)

Country Link
US (3) US11179354B2 (fr)
EP (1) EP3618821B8 (fr)
AU (1) AU2018217038B2 (fr)
CA (1) CA3071385A1 (fr)
DK (1) DK3618821T3 (fr)
ES (1) ES3024479T3 (fr)
FI (1) FI3618821T3 (fr)
HR (1) HRP20250377T1 (fr)
HU (1) HUE071486T2 (fr)
LT (1) LT3618821T (fr)
PL (1) PL3618821T3 (fr)
PT (1) PT3618821T (fr)
SI (1) SI3618821T1 (fr)
WO (1) WO2018144570A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827222B2 (en) 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
EP3618821B8 (fr) 2017-01-31 2025-04-23 NephroDI Therapeutics, Inc. Gestion du diabète insipide néphrogène
US20230364039A1 (en) * 2020-10-14 2023-11-16 Emory University Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864381A (en) 1996-07-10 1999-01-26 Sandia Corporation Automated pupil remapping with binary optics
US7335689B2 (en) 2003-01-23 2008-02-26 Esperion Therapeutics, Inc. Dihydroxyl compounds and compositions for cholesterol management and related uses
WO2006060079A2 (fr) * 2004-10-25 2006-06-08 University Of Utah Research Foundation Methodes et compostions de traitement du diabete insipide nephrogenique
CN103327974A (zh) 2010-09-20 2013-09-25 卡留斯治疗公司 用于治疗糖尿病和血脂异常的方法和组合物
US20140121267A1 (en) 2011-09-20 2014-05-01 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia
US9827222B2 (en) 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
WO2015101609A1 (fr) 2013-12-31 2015-07-09 Stichting Katholieke Universiteit Méthode de traitement d'affections rénales
EP3618821B8 (fr) 2017-01-31 2025-04-23 NephroDI Therapeutics, Inc. Gestion du diabète insipide néphrogène

Also Published As

Publication number Publication date
US20240139127A1 (en) 2024-05-02
HRP20250377T1 (hr) 2025-07-18
PT3618821T (pt) 2025-05-14
US20220031639A1 (en) 2022-02-03
LT3618821T (lt) 2025-05-26
AU2018217038A1 (en) 2020-07-02
CA3071385A1 (fr) 2018-08-09
US11844770B2 (en) 2023-12-19
WO2018144570A1 (fr) 2018-08-09
EP3618821B1 (fr) 2025-03-12
EP3618821A4 (fr) 2021-03-03
PL3618821T3 (pl) 2025-07-07
SI3618821T1 (sl) 2025-07-31
EP3618821B8 (fr) 2025-04-23
EP3618821A1 (fr) 2020-03-11
AU2018217038B2 (en) 2023-07-06
US11179354B2 (en) 2021-11-23
US12433858B2 (en) 2025-10-07
DK3618821T3 (da) 2025-04-07
HUE071486T2 (hu) 2025-09-28
US20200383940A1 (en) 2020-12-10
FI3618821T3 (fi) 2025-06-20

Similar Documents

Publication Publication Date Title
US12433858B2 (en) Substituted cycloalkanes for managing nephrogenic diabetes insipidus
ES2911207T3 (es) Composiciones de insulina de acción rápida
ES2702848T3 (es) Complejos de flumazenil, composiciones que los comprenden y usos de los mismos
ES2683902T3 (es) Administración de benzodiacepina
ES2507491T3 (es) Preparación farmacéutica que comprende un inhibidor de DPP-IV y otros agentes terapéuticos de la diabetes en forma concomitante o combinada
ES2627944T3 (es) Composiciones y métodos de tratamiento de hipertensión pulmonar
TWI763632B (zh) 用於重症治療時之鎮靜方法及非口服調配物
ES2779006T3 (es) Composiciones de DNJ parenterales estables
JP2020520963A (ja) 抑うつ障害の処置
ES2383433T3 (es) Formulación farmacéutica de apomorfina para administración bucal
ES2903136T3 (es) Clorhidrato de creatina para el tratamiento de la enfermedad de Huntington
ES2399569T3 (es) Composición farmacéutica líquida estable a base de trazodona
ES2358931T3 (es) Uso de un inhibidor de quinasa p38 para el tratamiento de trastornos psiquiatricos.
EP1543826A1 (fr) Solution aqueous concentree de ambroxol
ES2239042T3 (es) Nueva combinacion para el tratamiento de la disfuncion sexual.
ES2634026T3 (es) Composiciones medicinales
ES2617235T3 (es) Uso de pidotimod para tratar psoriasis
ES2370790A1 (es) Uso de oxalacetato en el tratamiento de isquemia.
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
WO2016024369A1 (fr) Composition médicinale pour le traitement du cancer
ES2992016T3 (es) Una solución acuosa estable de hidroxicarbamida
WO2012049550A1 (fr) Composition pharmaceutique liquide pour le traitement et la prévention de la douleur
ES2761311T3 (es) Tratamiento terapéutico
ES2754449T3 (es) Acido carboxílico de pirrolidona (pca) para uso oftálmico
EP4518848A1 (fr) Baclofène intranasal